Individual Submission Summary
Share...

Direct link:

Medicaid 1115 Waivers and Access to SUD Treatment and Supportive Services

Thursday, November 5, 1:45 to 3:15pm, Property: Boston Marriott Copley Place, Floor: 3rd Floor, Room: Clarendon

Abstract

Medicaid 1115 substance use disorder (SUD) Institution for Mental Disease (IMD) waivers are a policy mechanism used by statesto secure federal approval to provide a wide variety of care not typically covered by Medicaid. Despite growing interest in these waivers as a tool for addressing gaps in care continuity, current evidence on waiver effectiveness has been mixed.
To address the gaps in the existing literature, we collected all of the most recently approved waiver documents for SUD/IMD Medicaid 1115 waivers, assembling a comprehensive dataset covering 37 states’ approved waivers and compiling SUD service availability and specific coverage details. We then descriptively analyzed the quantitative dataset and grouped results by service category (basic SUD treatment offerings, medications for OUD and AUD, and recovery and other supportive services).
The number of SUD treatment services and medications covered by states using the 1115 IMD SUD waiver ranged from one to 13. Most states used the waiver to expand residential services (86.5%), withdrawal management (75.7%), early intervention services (73.0%), and inpatient services (64.9%), although some states also used the waiver to expand outpatient services (24.3%) and auxiliary supports such as peer support (29.7%). Many states also used the waiver to expand medication for opioid use disorder (MOUD) and alcohol use disorder (MAUD), with 59.5% of states indicating they used the waiver for some form of MOUD or MAUD. Given substantial heterogeneity in waiver design, evaluations should move beyond binary waiver indicators to account for the specific services and populations each waiver covers.

Authors